GHRS Stock Forecast & Price Target

GH Research is supported by a compelling TRD profile for GH001, with Phase IIb data showing a -15.5-point placebo-adjusted MADRS reduction at Day 8, 57.5% remission versus 0% on placebo, and 73% remission at 6 months, which underpins confidence in its practice-changing potential. The company also removed major execution risks after July 2026 FDA feedback confirmed CMC and the proprietary aerosol delivery device appear Phase III ready, while Phase I device PK and U.S. IND-opening studies were completed and pivotal doses selected. With Phase III site selection already done, a limited-center design that should aid enrollment, and multiple investigator requests for IITs after JAMA Psychiatry publication earlier this year, the fundamentals suggest strong clinical momentum and expanding optionality.

GH Research is burdened by outsized clinical and regulatory uncertainty, with GH001 still subject to FDA clinical hold risk, possible delays in lifting that hold, and the chance that a Phase III study fails to reproduce earlier efficacy or reveals new safety or tolerability issues. Even with about $362.7MM in cash, cash equivalents, and marketable securities as of June 30, 2026, the company remains a single-segment R&D story that depends on capital-intensive pivotal execution, potential commercialization, and eventual financing without any product revenue to offset losses. Competitive threats from more established TRD therapies and other psychedelics, plus possible DEA rescheduling barriers and manufacturing or device issues, further weaken the long-term fundamental case.